Please assess the completion status of the following clinical trial:

Trial Title: Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
1. Inclusion Criteria for relapse Group :~   * Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis~  * Obtention of oral and written consent of the parents~  * Parents affiliated with the social security system~2. Inclusion Criteria for control Group :~   * Children aged from 1 to 18 years enrolled into FRALLE or EORTC treatment protocols, treated for B-ALL and who are in complete molecular remission~  * Obtention of oral and written consent of the parents~  * Parents affiliated with the social security system~3. Exclusion criteria for control Group are the same as for relapsed Group :~   * Children with hematologic syndrome predisposing to hematologic neoplasia (such as Fanconi's anaemia, Diamond Blackfan anaemia ...) or acute leukemia secondary to previous treatment, or who have had allogenic hematopoietic stem cell transplantation before relapse

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Relapse Group (Type: OTHER): * Collection of blood samples will be done in newly diagnosed relapse of B-ALL children at the time of relapse diagnosis.~* Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis.
- Control Group (Type: OTHER): * Collection of blood samples will be done at the same stage of treatment as the relapse group has been collected.~* Children aged from 1 to 18 years enrolled into FRALLE (protocol of treatment) or EORTC (European Organisation for Research and Treatment of Cancer) treatment protocols, treated for B-ALL and who are in complete molecular remission.~* These control patients will be recruited at the same time from the beginning of B-ALL treatment as paired-relapsed control patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).